Ionis Releases News about Clinical Trial of ION582

November 11, 2024

Ionis Pharmaceuticals has released information regarding their clinical trial of ION582. The trial will move into Phase 3 and will be called Reveal.

Ionis will be presenting more information at the FAST Global Science Summit on Saturday, November 9th at 10:10am EST.

Read the community letter.

Read the press release.

Ultragenyx Pharmaceutical Receives Breakthrough Therapy Designation from FDA for GTX-102

Learn more

First Patient(s) Dosed in Ionis Phase 3 ION582 Study

Learn more

MavriX Bio Announces New Potential Gene Therapy for Angelman Syndrome

Learn more

Oak Hill Bio Obtain Global Rights for Rugonersen

Learn more

More News & Blogs

The mission of Angelman Syndrome Foundation is to advance the awareness and treatment of Angelman syndrome through education and information, research and support for individuals with Angelman syndrome, their families and other concerned parties. We exist to give all of them a reason to smile, with the ultimate goal of finding a cure.

3015 E. New York Street, Suite A2 #285
Aurora, IL 60504
(800) 432-6435
info@angelman.org